As global markets continue to experience fluctuations, with Asian indices showing resilience amid geopolitical tensions and economic shifts, investors are increasingly focusing on companies with ...
Launched KOMZIFTI™ (ziftomenib), first and only once-daily, oral menin inhibitor approved for adults with R/R NPM1-mutated ...
YUEQING, ZHEJIANG, CHINA, January 8, 2026 /EINPresswire.com/ -- As global energy systems transition towards digitalized ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback